Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. McGuire DK, Marx N, Mulvagh SL, Deanfield JE, et al. N Engl J Med 2025 Mar 29. doi: 10.1056/NEJMoa2501006.

Read + Share

Amedeo Smart

Independent Medical Education

McGuire DK, Marx N, Mulvagh SL, Deanfield JE, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med 2025 Mar 29. doi: 10.1056/NEJMoa2501006.
PMID: 40162642